Comparative Pharmacology
Head-to-head clinical analysis: DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE versus KOMBIGLYZE XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE versus KOMBIGLYZE XR.
DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE vs KOMBIGLYZE XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs incretin hormone activity, enhancing insulin secretion and decreasing glucagon release.
KOMBIGLYZE XR is a combination of saxagliptin, a DPP-4 inhibitor, and metformin, an AMPK activator. Saxagliptin increases incretin levels (GLP-1, GIP) by inhibiting DPP-4, leading to increased insulin release and decreased glucagon secretion. Metformin decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity.
Oral, 5 mg dapagliflozin / 5 mg saxagliptin once daily, with or without food.
One tablet orally once daily with food; available strengths: saxagliptin 5 mg/metformin extended-release 500 mg, saxagliptin 5 mg/metformin extended-release 1000 mg. Titrate based on glycemic response and tolerability.
None Documented
None Documented
Dapagliflozin: terminal half-life ~12.9 hours after oral dose, supporting once-daily dosing. Saxagliptin: terminal half-life ~2.5 hours for parent drug; its active metabolite has half-life ~3.1 hours; overall DPP-4 inhibition sustained for 24 hours.
Terminal elimination half-life for saxagliptin is 2.5 hours and for its active metabolite is 3.1 hours; clinical context: no significant accumulation at steady state.
Dapagliflozin: 75% renal (mainly as inactive glucuronide metabolite, 2% as parent drug), 21% fecal. Saxagliptin: 75% renal (metabolites, 24% as parent drug), 22% fecal. Biliary: negligible.
Renal excretion of unchanged saxagliptin (24%) and its active metabolite 5-hydroxy saxagliptin (22%); fecal excretion of parent (0.3%) and metabolite (6%); total renal elimination accounts for approximately 75% of the administered dose.
Category A/B
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor + Biguanide Combination